Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
To read the full story
Related Article
- Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
August 29, 2023
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
BUSINESS
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
- Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
Your reputation as an employer matters.A survey completed by Indeed found that 95% of job seekers found a company’s reputation was an important consideration.When top talent is a scarce commodity, companies need to do more than just make an offer.…
A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…